-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On January 10, the official website of CDE showed that the clinical application of Sunshine Guojian's monoclonal antibody SSGJ-617 targeting PSGL-1, a subsidiary of 3SBio, was accepted by the State Food and Drug Administration
SSGJ-617 (VTX-0811) was developed by Verseau.
PSGL-1 is the first target in Verseau's pipeline of macrophage checkpoint modulators to enter development
On November 18, 2019, 3SBio and Verseau reached a licensing agreement to select VTX-0811 as the first licensed product